



DATE	STOCK	RECOMD	ENTRY PRICE	TARGET	STOP LOSS
28.06.2021	HDFCBANK	BUY	1515	1560	1480
28.06.2021	SBILIFE	BUY	1007	1045	990

NOTE –These Stocks are recommended only for short term investment (Stop Loss should be followed Daily closing basis).

### TECHNICAL OUTLOOK

NIFTY WEEKLY CLOSE – 15860.35 ( ↑ 177)

Last week, Nifty opened on a mild note at 15525, but moved up during the week. However, as seen from earlier week, Nifty is facing some resistance within 15830-15900 range. Nifty closed at 15860 with a gain of 177 points.

Nifty remains above its key daily as well as weekly EMAs. Daily as well as weekly RSI is placed above respective averages.

Going ahead, Nifty is likely to move in the range near 15800-15900. A strong above this will take it towards 16000. On the other hand, breaching 15500-15450 could take Nifty near 15270.





#### WEEKLY INVESTMENT IDEAS REVIEW

DATE	STOCK	RECOMD	ENTRY PRICE	TARGET	STOP LOSS	TODAY CLOSE	NET CHANGE (%)	REMARK
21.6.2021	GICRE	BUY	200	213	193	198.35	-0.83	Exit
21.6.2021	OIL	BUY	148	165	133	156.75	5.58	Exit (High 160)
21.6.2021	ZEEL	BUY	221	235	210	218.35	-1.21	Exit

#### WEEKLY MARKET REVIEW

### Sensex, Nifty log modest gains

Equity market in India witnessed positive move this week, supported by further decline in new COVID cases and increased pace of vaccination. Market upmove was broad-based with the BSE Mid-Cap and BSE Small-Cap indices also logging gains.

In the week ended on Friday, 25 June 2021, the Sensex rose 580.59 points or 1.11% to settle at 52,925.04. The Nifty 50 index rose 177 points or 1.13% to settle at 15,860.35. The BSE Mid-Cap index gained 311.44 points or 1.4% to settle at 22,549.65. The BSE Small-Cap index gained 347.40 points or 1.41% to settle at 24,996.23.

Maruti Suzuki India surged 9.84%. It has planned price hike in the second quarter due to higher input costs. The company's vehicles continue to be adversely impacted due to increase in various input costs. Hence, it has become imperative for the company to pass on some impact of the above additional cost to customers through a price rise.

State Bank of India (SBI) advanced 3.86%. Its board has approved raising additional tier-I capital of upto Rs 14,000 crore through Basel-III bonds. The central board of the PSU bank approved raising the funds through issue of Basel III-compliant debt instrument in USD and/or Indian rupees during FY22. The fund raise is subject to Government of India concurrence.

Reliance Industries (RIL) dropped 5.43%. RIL chairman and managing director Mukesh Ambani hosted the 44th annual general meeting virtually. Ambani said that the company's business grew despite challenges due to the Covid-19 pandemic. This was mainly due to a sharp increase in its consumer business, which now contributes roughly half of RIL's operating profit.

NTPC advanced 2.2%. The company's consolidated net profit surged 185.3% to Rs 4,649.49 crore on 0.9% slip in net sales to Rs 30,102.60 crore in Q4 March 2021

over Q4 March 2020. Profit before tax skid 14.38% to Rs 4,017.72 crore in Q4 FY21 as against Rs 4,692.53 crore in Q4 FY20. The board of NTPC has approved the enhancement of borrowing limit of the company to Rs 2,25,000 crore from Rs 2,00,000 crore.

HDFC Bank rose 2.32%. HDFC Bank board has approved to buy 3.56 crore shares or 4.99% stake in HDFC ERGO General Insurance Co. from its parent and mortgage lender Housing Development Finance Corporation. The aggregate consideration for purchase of 3,55,67,724 shares of Rs 10 each of HDFC ERGO is Rs 1,906.43 crore i.e. Rs 536 per share.

ONGC rose 0.46%. The PSU company's standalone net profit surged to Rs 4,762.86 crore in Q4 FY21 from Rs 836.86 crore in Q4 FY20. Net sales during the quarter declined by 1.2% to Rs 21,188.91 crore in Q4 FY21 over Q4 FY20. Net realisation increased by 18.4% to \$58.05 a barrel in the March quarter, compared with \$49.01 a barrel in the year-ago quarter.

Dr. Reddy's Labs rose 0.51%. The drug maker announced the launch of icosapent ethyl capsules, 1 gram in the US market. The product has received an approval by the USFDA. The drug is indicated to reduce triglyceride (TG) levels in adult patients with severe ( $\geq 500$  mg/dL) hypertriglyceridemia.

Vedanta gained 4.13%. The company has been awarded the Kuraloi (A) North coal block, located in Jharsuguda district, Odisha. The coal block is an optimal fit for the company's Jharsuguda smelter given its logistical location and annual capacity. The mine has geological reserves of 1,680 million tonnes and an estimated per annum capacity of 8 million tonnes. Once operational, it will provide fuel security, improve power availability and further strengthen the company's aluminium operations and performance.

Source: [www.capitalmarket.com](http://www.capitalmarket.com)



### SAJAG SECURITIES PVT. LTD.

MEMBER: NATIONAL STOCK EXCHANGE OF INDIA LTD.

MEMBER: BOMBAY STOCK EXCHANGE LTD.

DEPOSITORY PARTICIPANT: NATIONAL SECURITIES DEPOSITORY LTD.

DEPOSITORY PARTICIPANT: CENTRAL DEPOSITORY SERVICES LTD.

33/15 - B, KARVE ROAD, REGENT CHAMBERS, PUNE - 411004, TEL: 91-20-66014737, FAX: 91-20-25302555

email: [business@sajag.co.in](mailto:business@sajag.co.in) / [investorgrievance@sajag.co.in](mailto:investorgrievance@sajag.co.in)

NSE TM ID - 07549

BSE TM ID - 3105

NSDL DP ID: IN303647

CDSL DP ID: 12062400

SEBI Regn. No. INZ000221337

**Disclosure:** This report is issued by Sajag Securities Pvt. Ltd. (SSPL), a stock broking company, which is regulated by SEBI and its research activities are as per SEBI Guidelines for Research Analysts December 2014. Registration Number: INH000001923. This report is prepared and distributed by SSPL for information purpose only. SSPL and the research analyst(s) who prepared this report do not have any long or short positions in derivatives markets in any of the above mentioned securities. SSPL or the research analyst(s) do not have ownership of 1% or more in the company. The research analyst(s) who prepared this research report hereby certifies that the views expressed in this research report accurately reflect the research analyst's personal views about all of the subject issuers and/or securities, that the analyst(s) have no known material conflict of interest and no part of the research analyst's compensation was, is or will be, directly or indirectly, related to the specific views or recommendations contained in this research report.

**Disclaimer:** Neither the information contained herein nor any opinion expressed should be construed or deemed to be construed as solicitation or as offering advice for the purposes of the purchase or sale of any security or investment or derivatives. The information and opinions contained in the report were considered by SSPL to be valid when published. The report also contains information provided to SSPL by third parties. The source of such information will usually be disclosed in the report. While SSPL has taken all responsible steps to ensure that this information is correct, SSPL does not offer any warranty as to the accuracy or completeness of such information. Any person placing reliance on the report to undertake trading does so entirely at his/her own risk and SSPL does not accept any liability as a result. Securities and Derivatives markets may be subject to rapid and unexpected price movements and past performance is not necessarily a guide to future performance. The report does not have regard to the specific investment objective, financial situation and the particular needs of any specific person who may receive this report. Investor must undertake independent analysis with their own legal, tax and financial advisors and reach their own decision regarding the appropriateness of investing in any securities or investment strategies discussed and recommended in this report and should understand that statements regarding future prospects may not be realized. In no circumstances be it used or considered as an offer to sell or a solicitation of any offer to buy or sell the securities mentioned in it. The information contained in the research reports may have been taken from trade and statistical services and other sources, which we believe reliable. SSPL does not guarantee that such information is accurate or complete and it should not be relied upon as such. Any opinions expressed reflect judgments at this date and are subject to change without notice. The target prices mentioned in the report are based on certain assumptions as of the date appearing in the material and may be subject to change from time to time without notice.